deucravacitinib - Profile

What are the generic drug sources for deucravacitinib and what is the scope of patent protection?

Deucravacitinib is the generic ingredient in one branded drug marketed by Bristol and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Deucravacitinib has one hundred and four patent family members in forty countries.

Summary for deucravacitinib

International Patents:	104
US Patents:	4
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for deucravacitinib

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for deucravacitinib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes	12,521,390		Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes	11,021,475
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes	RE47929		Y	Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes	10,000,480		Y	Y
Bristol	SOTYKTU	deucravacitinib	TABLET;ORAL	214958-001	Sep 9, 2022		RX	Yes	Yes

EU/EMA Drug Approvals for deucravacitinib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Sotyktu	deucravacitinib	EMEA/H/C/005755Treatment of moderate-to-severe plaque psoriasis in adults.	Authorised	no	no	no	2023-03-24

International Patents for deucravacitinib

Country	Patent Number	Title	Estimated Expiration
Lithuania	3495358
Japan	2020002157
Netherlands	301238
Poland	3495358
Peru	20150944
Brazil	112015010102	compostos heterocíclicos substituídos por amida úteis como moduladores de respostas de il-12, il-23 e/ou ifnalfa
Slovenia	3495358

Supplementary Protection Certificates for deucravacitinib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2922846	LUC00313	Luxembourg		PRODUCT NAME: DEUCRAVACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1718 20230327
2922846	202340016	Slovenia		PRODUCT NAME: DEUCRAVACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; NATIONAL AUTHORISATION NUMBER: EU/1/23/1718; DATE OF NATIONAL AUTHORISATION: 20230324; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2922846	CR 2023 00024	Denmark		PRODUCT NAME: DEUCRAVACITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/23/1718 20230327
2922846	CA 2023 00024	Denmark		PRODUCT NAME: DEUCRAVACITINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/23/1718 20230327
2922846	PA2023523,C2922846	Lithuania		PRODUCT NAME: DEUKRAVACITINIBAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1718 20230324
2922846	2023C/531	Belgium		PRODUCT NAME: DEUCRAVACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/23/1718 20230327
2922846	23C1030	France		PRODUCT NAME: DEUCRAVACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1718 20230327

Deucravacitinib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

Executive Summary

Deucravacitinib (BMS-986165), a selective TYK2 inhibitor developed by Bristol-Myers Squibb (BMS), positions itself as a transformative treatment for autoimmune disorders, prominently psoriasis. The drug's unique mechanism of action, favorable efficacy profile, and regulatory approvals signal strong commercial potential. This report evaluates the current market landscape, competitive positioning, regulatory pathway, projected sales trajectory, and investment risks.

---

1. Introduction to Deucravacitinib

Aspect	Details
Therapeutic Area	Autoimmune diseases, primarily moderate-to-severe plaque psoriasis
Mechanism of Action	Selective TYK2 inhibition targeting cytokine signaling pathways
Development Status	Approved by FDA (September 2022); EMA approval anticipated
Patent Horizon	Patent protection until at least 2030

---

2. Market Dynamics

2.1. Autoimmune Disease Market Landscape

Disease	Market Size (2022, USD billion)	Projected Growth (2023-2028)	Key Competitors
Moderate-to-severe Psoriasis	15	8.5% CAGR	Humira, Stelara, Cosentyx, Taltz
Psoriatic Arthritis	5.7	7.2% CAGR	Taltz, Otezla, Stelara
Ulcerative Colitis & Crohn’s Disease	14.5	6.8% CAGR	Humira, Rinvoq, Stelara, Skyrizi

Note: The psoriasis segment dominates the TYK2 inhibitor's initial indication.

2.2. Key Market Drivers

• Growing prevalence: Psoriasis affects approximately 2-3% of the global population (~125 million people).
• Unmet needs: Moderate-to-severe cases often lack effective, safe, long-term oral options.
• Patient preference: Oral small molecules preferred over injectables for ease of administration.
• Regulatory momentum: FDA approval established a commercial foundation; EMA and other jurisdictions likely follow.

2.3. Competitive Landscape Analysis

Drug	Class	Route	Market Launch	Key Indication	Annual Sales (2022, USD billion)	Patent Expiry
Deucravacitinib	TYK2 inhibitor	Oral	2022	Psoriasis	N/A (launch phase)	2030+
Otezla (apremilast)	PDE4 inhibitor	Oral	2014	Psoriasis, PsA	2.2	2029
Cosentyx (secukinumab)	IL-17A monoclonal antibody	Injection	2015	Psoriasis	7.2	2030
Stelara (ustekinumab)	IL-12/23 monoclonal antibody	Injection	2009	Psoriasis, PsA	8.2	2030
Taltz (ixekizumab)	IL-17A monoclonal antibody	Injection	2016	Psoriasis	3.7	2034

Note: The competitive advantage for deucravacitinib lies in its oral route, safety profile, and targeted mechanism.

---

3. Regulatory and Commercial Trajectory

3.1. FDA Approval and Post-Launch Outlook

• Approval Date: September 2022
• Indication: Moderate-to-severe plaque psoriasis
• Launch Strategy: Direct commercialization via BMS's specialty sales force; potential partnerships for broader indications

3.2. Expansion Opportunities

Indication	Development Stage	Potential Launch Year	Market Size (USD billion)
Psoriatic Arthritis	Phase 3 underway	2024-2025	5.7
Ulcerative Colitis / Crohn’s	Phase 2/3 ongoing	2025-2026	14.5
Other autoimmune conditions	Investigational	N/A	N/A

3.3. Regulatory Pathway and Approvals

• FDA: Approved under Priority Review due to unmet needs.
• EMA: Application submitted; approval anticipated within 12-18 months.
• Key Conditions: Demonstrating sustained efficacy, tolerability, and safety in extended trials.

---

4. Financial Projections and Sales Forecast

4.1. Assumptions for Revenue Model

Factor	Assumption
Launch Year	2022
Peak Market Penetration	25% of the psoriasis market (~3.75 million patients globally)
Average Price (2022 USD)	$45,000 per patient annually
Year-over-Year Growth for Sales	15% post-peak, considering expanding indications
Market Share Growth Rate	5% annually post-launch

4.2. 5-Year Sales Projection (2022-2026)

Year	Estimated Patients on Drug	Market Penetration	Approximate Sales (USD billion)	Notes
2022	0.2 million	1%	0.009	Initial launch, early access
2023	0.8 million	5%	0.36	Commercial expansion
2024	1.5 million	10%	0.675	Broader access, indications
2025	2.4 million	16%	1.08	Market growth, new indications
2026	3.75 million	25%	1.69	Peak sales achievement

Note: These figures are conservative; market dynamics and competition could significantly impact actual sales.

4.3. Long-term Financial Outlook

Year	Projected Cumulative Revenue	Major Drivers
2027	USD 2.8 billion	Expanded indications; global coverage
2030	USD 4.5 billion	Market saturation; patent exclusivity

---

5. Investment Risks and Challenges

Risk Factor	Description	Mitigation Strategies
Competitive Pressure	Entry of biosimilars or new orally active agents	Maintain innovation pipeline; lifecycle management
Regulatory Changes	Stringent approval processes or delays	Engage early with regulators; adaptive strategies
Patent Challenges	Litigation or patent invalidation issues	Strong patent portfolio; proactive legal actions
Market Penetration	Slower-than-expected adoption in primary markets	Robust sales and marketing; physician education
Safety Profile Concerns	Unexpected adverse events post-approval	Continued safety monitoring; transparent communication

---

6. Market Comparisons

Aspect	Deucravacitinib	Competing Biologics	Small Molecule Alternatives
Route of Administration	Oral	Injectable	Oral
Time to Market	Approved (2022)	Approved (2015-2022)	Established
Patent Life Remaining	~7 years (until ~2030)	8-15 years remaining	5-10 years
Competitive Edge	Selectivity, safety, convenience	Established efficacy, injectables	Oral, lower cost, safety concerns

---

7. Key Differentiators and Commercial Edge

• Oral administration: Enhances patient adherence and preference.
• Targeted mechanism: Selectively inhibiting TYK2 reduces systemic immunosuppression.
• Regulatory approval: First-in-class TYK2 inhibitor grants early market share advantage.
• Potential for pipeline expansion: Indications beyond psoriasis.

---

8. Conclusion: Investment Outlook Summary

Deucravacitinib presents a robust entry into the autoimmune therapeutics space with significant growth prospects driven by its novel mechanism, oral formulation, and early approval advantage. The key to maximizing value lies in successful expansion into adjunct indications such as psoriatic arthritis and ulcerative colitis, sustained safety profile, and capturing global markets amid competition.

---

9. Key Takeaways

• Market Positioning: Leading the TYK2 inhibitor class with a clear first-mover advantage.
• Growth Potential: Projected USD 4.5 billion in peak sales by 2030.
• Competitive Dynamics: Faces competition from biologics and emerging small molecules; differentiation relies on safety and convenience.
• Regulatory Pathways: Ongoing submissions for additional indications; regulatory timelines critical.
• Investment Risks: Market adoption, patent challenges, and competitive encroachment warrant close monitoring.

---

10. FAQs

Q1: How does deucravacitinib differ mechanistically from existing psoriasis treatments?
A: It selectively inhibits TYK2, a kinase involved in cytokine signaling, offering targeted immunomodulation differing from broader immunosuppressants like biologics targeting IL-17, IL-12, or TNF-alpha.

Q2: What are the major competitors to deucravacitinib in psoriasis treatment?
A: Biologic agents like Secukinumab (Cosentyx), Ustekinumab (Stelara), and other oral options like apremilast (Otezla).

Q3: What drives the commercial success of deucravacitinib?
A: Combination of efficacy, oral administration, favorable safety profile, and first-mover advantage.

Q4: When are additional indications expected to launch?
A: Psoriatic arthritis trials are underway, with potential launch between 2024-2025; ulcerative colitis data expected by 2025-2026.

Q5: What risks could impede deucravacitinib's market penetration?
A: Intense competition, safety concerns, regulatory delays, patent disputes, and slower-than-expected market adoption.

---

References

1. Bristol-Myers Squibb. (2022). FDA approves deucravacitinib for psoriasis.
2. GlobalData. (2023). Autoimmune Disease Market Reports.
3. EvaluatePharma. (2023). 2023 Pharmaceutical Sales Data.
4. Company disclosures and pipeline summaries.
5. Regulatory filings and clinical trial registries.